Literature DB >> 3915459

Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis.

E Masci, P A Testoni, S Passaretti, M Guslandi, A Tittobello.   

Abstract

In the treatment of reflux oesophagitis, either drugs preventing regurgitation of gastric juice in the lower oesophagus or pharmacological agents increasing the pH of the refluxing material are employed. In the present study 45 outpatients with reflux oesophagitis were randomly treated with either ranitidine (150 mg b.i.d.) or domperidone maleate (20 mg t.i.d.) or both drugs for six weeks. Before and after treatment the severity of dyspeptic symptoms and the grade of endoscopic and histological changes were assessed. The three therapeutic regimens were significantly and equally effective in inducing symptomatic relief and promoting endoscopic and histological disappearance or improvement of oesophagitis. The combined use of ranitidine and domperidone maleate failed to show any additional benefit compared with treatment with either drug alone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3915459

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  5 in total

1.  Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Economic evaluation of long-term management strategies for erosive oesophagitis.

Authors:  R Goeree; B O'Brien; R Hunt; G Blackhouse; A Willan; J Watson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 3.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 4.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD: Implications for Treating Patient Subgroups.

Authors:  M Iskedjian; T R Einarson
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.